Reports Q2 revenue $743.3M, consensus $729.91M. “Our solid Q2 performance reflects the strength of our diversified product portfolio and global execution,” said Liam Kelly, Teleflex’s Chairman, President and CEO. “The global environment was stable during the second quarter, and we expect a continuation in the second half of 2023. In addition, we took an important step forward in our durable growth strategy with the agreement to acquire Palette Life Sciences AB. The acquisition of Palette provides us with a high growth portfolio featuring a sculptable rectal spacer that will expand our Interventional Urology franchise with complementary adjunctive therapy for prostate cancer, which we expect will contribute meaningfully to our growth in the coming years.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TFX:
- Teleflex Announces Quarterly Dividend
- Teleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook
- Teleflex participates in a conference call with CL King
- Teleflex management to meet virtually with Stephens
- Teleflex: FDA clears expanded indication for QuikClot Control Hemostatic Device
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue